Celldex Therapeutics (CLDX) Enterprise Value (2016 - 2025)
Celldex Therapeutics (CLDX) has 16 years of Enterprise Value data on record, last reported at -$518.6 million in Q4 2025.
- For Q4 2025, Enterprise Value rose 28.5% year-over-year to -$518.6 million; the TTM value through Dec 2025 reached -$518.6 million, up 28.5%, while the annual FY2025 figure was -$518.6 million, 28.5% up from the prior year.
- Enterprise Value reached -$518.6 million in Q4 2025 per CLDX's latest filing, up from -$583.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$164.0 million in Q2 2021 and bottomed at -$823.8 million in Q1 2024.
- Average Enterprise Value over 5 years is -$462.0 million, with a median of -$415.7 million recorded in 2021.
- Peak YoY movement for Enterprise Value: tumbled 227.77% in 2021, then increased 29.18% in 2023.
- A 5-year view of Enterprise Value shows it stood at -$408.2 million in 2021, then rose by 25.3% to -$305.0 million in 2022, then crashed by 38.91% to -$423.6 million in 2023, then tumbled by 71.22% to -$725.3 million in 2024, then grew by 28.5% to -$518.6 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$518.6 million in Q4 2025, -$583.2 million in Q3 2025, and -$630.3 million in Q2 2025.